NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
- None.
- None.
Insights
The announcement from NRx Pharmaceuticals concerning the completion of their Phase 2b/3 study for NRX-101 marks a critical juncture for the company with significant financial implications. The forthcoming statistical analysis and top-line data will be closely scrutinized by investors, as positive results could lead to a $4 million milestone payment from partners Alvogen and Lotus, along with the assumption of further development costs. This is part of a larger agreement that could yield up to $329 million in milestone payments plus royalties on net sales, which are anticipated to be in the mid-teens percentage range.
From a financial perspective, the success of NRX-101 could substantially alter the revenue projections for NRx Pharmaceuticals. The Breakthrough Therapy Designation and other FDA endorsements could streamline the path to market, potentially leading to a competitive advantage in the treatment of suicidal bipolar depression, a market currently underserved. However, it's important to note that the company's valuation and stock price may experience volatility around the release of the top-line data, as market sentiment will react to the perceived efficacy and safety profile of the drug.
The clinical development of NRX-101, if successful, could represent a significant advancement in the treatment of Suicidal Treatment Resistant Bipolar Depression. The maintained 95% concordance rate between study sites and central raters on the primary endpoint suggests a high level of data reliability and accuracy, which is crucial for the integrity of the study's findings. The absence of unexpected Serious Adverse Events further underscores the potential safety profile of the drug, an essential factor in the FDA's assessment process.
Given that bipolar depression has a high mortality rate, with one in five patients reportedly losing their lives to the disease, the introduction of NRX-101 could meet a substantial unmet medical need. The drug's unique status as the only oral medication to have shown a reduction in suicidal ideation in this patient population could position it as a first-line treatment option, pending positive trial results and regulatory approval. This would not only impact patient care but could also significantly influence market dynamics within the psychiatric medication sector.
In analyzing the potential market impact of NRX-101, it's important to consider the prevalence of bipolar disorder and the subset of patients with suicidal ideation. Current treatments for bipolar depression often fail to address suicidal thoughts effectively, which presents a substantial opportunity for NRx Pharmaceuticals. Should NRX-101 gain approval, the market demand could be considerable, given the Breakthrough Therapy and Fast Track Designations by the FDA.
Moreover, the company's strategy to conduct the first outpatient clinical trial for this condition speaks to a broader trend in healthcare towards more accessible and patient-centric treatment approaches. This could resonate well with both healthcare providers and patients, potentially facilitating rapid adoption of the drug. However, the long-term market success of NRX-101 will depend on various factors, including competitive pricing, insurance coverage and the establishment of strong distribution channels.
- Marks a major step in the development of what could be the first drug approved for Suicidal Bipolar Depression
- The study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter
- Study maintained
95% concordance rate between study sites and central raters on primary endpoint. No unexpected Serious Adverse Events were reported. - Positive data and FDA comment would trigger the next
$4 million $329 million
NRX-101 has been awarded Breakthrough Therapy Designation, Fast Track Designation, a Biomarker Letter of Support, and a Special Protocol Agreement by the FDA for treatment of suicidal bipolar depression. It is the only oral medication to have demonstrated reduced suicidal ideation in patients with bipolar depression, a lethal disease that claims the lives of one in five who live with it.
"This is the first clinical trial, to the company's knowledge, conducted among patients with suicidal bipolar depression in the outpatient setting. Our previous trial measured the ability of NRX-101 to maintain the anti-depressant and anti-suicidal effect of ketamine administered in the hospital setting. These patients, whose clinical need is urgent and extraordinary have routinely been excluded from the clinical trials of all previously-known anti-depressant drugs. said Dr. Jonathan Javitt, Founder, Chairman and Chief Scientist of NRx Pharmaceuticals. Although there were patients whose depression worsened and required hospitalization (we don't yet know whether they were on NRX-101 or comparator), patient safety was maintained, and no trial participant suffered a serious unexpected adverse outcome. Our thanks go out to our investigators, clinics, partners and, most importantly, our amazing patients and their families for seeing this study through to this important milestone," "
The Phase 2b/3 trial (www.clinicaltrials.gov NCT 03395392) is a randomized, prospective, multicenter, double-blind study comparing NRX-101 to lurasidone over six weeks. The Principal Investigator is Prof. Andrew Nierenberg of Harvard Massachusetts General Hospital. The primary efficacy endpoint is reduction in depression as measured on the MADRS scale and the secondary endpoint is reduction of suicidal ideation as measured by the Clinical Global Impression Suicidality Scale (CGI-SS). As previously disclosed, treatment compliance and concordance of local raters to central raters scores was in excess of
Top-line results are expected around the end of this quarter.
About NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx has partnered with Alvogen and Lotus around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced plans to submit a New Drug Application for HTX-100 (IV ketamine), through Hope Therapeutics, in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a Specialty Pharmaceutical Company, wholly-owned by NRX Pharmaceuticals focused on development and marketing of an FDA-approved form of intravenous ketamine for the treatment of acute suicidality and depression together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding the proposed public offering and the timing and the use of the proceeds from the offering. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy and liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-nasdaq-nrxp-announces-last-patient-last-visit-in-its-phase-2b3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-depression-302078041.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the status of NRx Pharmaceuticals' Phase 2b/3 study for NRX-101 in Suicidal Bipolar Depression?
What are the key designations and agreements related to NRX-101 for Suicidal Bipolar Depression?
Who is the Principal Investigator of NRx Pharmaceuticals' Phase 2b/3 trial for NRX-101?
What are the primary and secondary endpoints of the Phase 2b/3 trial for NRX-101?
When are the top-line results of the Phase 2b/3 trial expected?
